{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:26:26Z","timestamp":1760149586781,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: Previous research has shown different effects of hematological malignancies on the outcome of patients with COVID-19 infection depending on the type of disease and the treatment received. This research was aimed at examining the clinical outcome of COVID-19 infection in positive patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Methods: We collected retrospective information on chronic myeloid leukemia patients who were treated and monitored in our institution during the pandemic period. Within this cohort, we recorded COVID-19 positive symptomatic patients and analyzed their basic characteristics, symptoms, severity, and outcome. Results: In the study cohort when COVID-19 was diagnosed, 86.7% of patients were on first-generation tyrosine kinase inhibitors therapy\u2014imatinib. At the time of infection, 70% of patients were in molecular remission, 23.4% in complete cytogenetic remission, and 3.3% in complete hematological response. Most patients had symptomatic disease. Within the analyzed group, 56.7% of patients had asymptomatic\/mild COVID-19 infection, 23.3% of patients had moderate symptoms which did not require hospitalization, and 20% of patients had severe\/critical symptoms that required admission to the intensive care unit. More than half of the patients interrupted treatment with tyrosine kinase inhibitors temporarily during COVID-19. There were no deaths due to COVID-19 infection. Conclusions: In compliance with other larger clinical studies, analysis of the clinical outcome of COVID-19 infection in patients with chronic myeloid leukemia on tyrosine kinase inhibitors therapy in this study showed that they do not have an increased risk for COVID-19 infection and that they have a mild course of the disease with recovery.<\/jats:p>","DOI":"10.3390\/medicina59091564","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T10:46:00Z","timestamp":1693305960000},"page":"1564","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection\u2014A Single Center Survey"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-1249","authenticated-orcid":false,"given":"Irena","family":"\u0106ojba\u0161i\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ni\u0161, Blvd. Zorana \u0110in\u0111i\u0107a 81, 18000 Ni\u0161, Serbia"},{"name":"Clinic of Hematology, Allergology and Clinical Immunology, University Clinical Centre Ni\u0161, Blvd. Zorana \u0110in\u0111i\u0107a 48, 18000 Ni\u0161, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Golubovi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Hematology, Allergology and Clinical Immunology, University Clinical Centre Ni\u0161, Blvd. Zorana \u0110in\u0111i\u0107a 48, 18000 Ni\u0161, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-1048","authenticated-orcid":false,"given":"\u017darko","family":"\u0106ojba\u0161i\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Mechanical Engineering, University of Ni\u0161, Aleksandra Medvedeva 14, 18000 Ni\u0161, Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.mayocp.2015.08.010","article-title":"Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015","volume":"90","author":"Thompson","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_3","first-page":"e7560","article-title":"A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19)","volume":"12","author":"Kakodkar","year":"2020","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicenter, cohort study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with hematological cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and metanalysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-020-0853-6","article-title":"COVID-19 in persons with chronic myeloid leukemia","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-142454","article-title":"Prevalence of SARS-CoV-2 Infection in Patients with Chronic Myeloid Leukemia","volume":"136","author":"Claudiani","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2021022","DOI":"10.4084\/mjhid.2021.022","article-title":"Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption","volume":"13","author":"Demeter","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4274\/tjh.galenos.2020.2020.0472","article-title":"COVID-19 in chronic phase chronic myeloid leukemia patients: A single-center survey from turkey","volume":"38","author":"Pekmezci","year":"2021","journal-title":"Turk. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/s41375-020-0904-z","article-title":"Chronic myeloid leukemia management at the time of the COVID-19 pandemic in italy. A campus CML survey","volume":"34","author":"Breccia","year":"2020","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1177\/1078155220953198","article-title":"Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","volume":"26","author":"Ata","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjh.17890","article-title":"COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report","volume":"196","author":"Breccia","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_14","unstructured":"(2020). Country & Technical Guidance\u2014Coronavirus Disease (COVID-19), World Health Organization. Available online: https:\/\/www.who.int\/covid-19."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/bcp.14353","article-title":"Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic","volume":"86","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J. Gen. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fonc.2020.01428","article-title":"Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: A possible model supporting their use in the fight against SARS-CoV-2","volume":"10","author":"Galimberti","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1152\/ajplung.00031.2015","article-title":"Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury","volume":"309","author":"Rizzo","year":"2015","journal-title":"Am. J. Physiol. Cell Mol. Physiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s13063-020-04819-9","article-title":"Safety and efficacy of imatinib for hospitalized adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Emadi","year":"2020","journal-title":"Trials"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140161","article-title":"COVID-19 in patients with chronic myeloid leukemia: Results from the international CML Foundation (iCMLf) CML and COVID-19 (CANDID) study","volume":"136","author":"Rea","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2020031","DOI":"10.4084\/mjhid.2020.031","article-title":"SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): A case report and review of ABL kinase involvement in viral infection: CML and COVID-19","volume":"12","author":"Abruzzese","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11912-021-01169-w","article-title":"What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?","volume":"24","author":"Delgado","year":"2022","journal-title":"Curr. Oncol. Rep."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1564\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:41:19Z","timestamp":1760128879000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,28]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medicina59091564"],"URL":"https:\/\/doi.org\/10.3390\/medicina59091564","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,8,28]]}}}